United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $564.51, for a total transaction of $5,362,845.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $183,151,317.93. The trade was a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR traded up $20.44 during trading on Monday, hitting $582.46. The company’s stock had a trading volume of 559,569 shares, compared to its average volume of 557,193. The company has a 50-day moving average of $533.99 and a 200-day moving average of $533.42. United Therapeutics Corporation has a 12 month low of $445.81 and a 12 month high of $614.23. The firm has a market cap of $24.81 billion, a price-to-earnings ratio of 21.98, a P/E/G ratio of 3.78 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The business had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business posted $7.16 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.77 earnings per share for the current year.
Wall Street Analyst Weigh In
UTHR has been the topic of several analyst reports. Leerink Partners lifted their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. The Goldman Sachs Group reissued a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a research report on Thursday, October 15th. Royal Bank Of Canada upped their price objective on United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a research note on Thursday. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 target price on shares of United Therapeutics in a report on Monday, October 26th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $676.40.
Get Our Latest Stock Analysis on United Therapeutics
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in United Therapeutics during the second quarter valued at about $2,868,735,000. Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of United Therapeutics in the second quarter valued at about $450,140,000. First Trust Advisors LP lifted its position in shares of United Therapeutics by 23.5% in the first quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock valued at $160,447,000 after acquiring an additional 51,555 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of United Therapeutics in the second quarter worth about $159,522,000. Institutional investors own 94.08% of the company’s stock.
About United Therapeutics
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.
Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
